Please upgrade your browser.
Senators are questioning high salaries and expensive travel bills for executives at the Boys & Girls Clubs of America, raising issues that could jeopardize millions in federal funding for the national charity.
[Ed. note: The Kidney Cancer Association is ranked as a 4-Star charity, the highest rating, by Charity Navigator, putting it ahead of much larger charities, such as the American Cancer Society.]
Rationing body rejects ten drugs (allowed in Europe) that could have extended lives. Is the practice of medicine in the USA headed down this same path?
Would I do it all again? Absolutely. I couldn't not do it again.
A presentation entitled A phase 2 multicenter, randomized, open-label study of two dose levels of IMO-2055 in patients with metastatic or recurrent renal cell carcinoma was made at the Eighth International Kidney Cancer Symposium.
A new way to provide clear images of cancerous tumors in the kidney during surgery promises to help physicians preserve as much kidney function as possible while still removing all the malignant tissue a significant advance as doctors discover that saving as much healthy kidney tissue as possible is crucial for the future health of cancer patients.
Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network
Xp11 translocation renal cell carcinoma (RCC) is an RCC subtype affecting 15% of RCC patients <45 years. We analyzed the benefit of targeted therapy [vascular endothelial growth factor receptor (VEGFR)-targeted agents and/or mammalian target of rapamycin (mTOR) inhibitors] in these patients.
Mr Jones asserts that the reduction or elimination of glucose in the diet and taking vitamin B17, together with a strict exercise regime, defeats cancer.
The number of patients required to give a statistically significant result depends on the question the trial wants to answer. For example, to show the effectiveness of a new drug in a non-curable disease as metastatic kidney cancer requires many fewer patients than in a highly curable disease as seminoma if the drug is compared to a placebo.
The company's lead product candidate is currently in last-stage development as a renal cell cancer treatment.
John Baron MP recently met with nurses, clinicians and patient representatives at an event in the House of Lords on 'Improving Outcomes for Kidney Cancer Patients'.
|Powered by NeonCRM|